Just caught Oculis' latest financials and there's actually some interesting momentum building here. Their cash position just jumped significantly to $268.7 million, which basically extends their runway through 2029 - that's solid footing for a clinical-stage biotech.

What caught my attention more though is the pipeline progression. Their lead candidate OCS-01 for diabetic macular edema is in two Phase 3 trials (DIAMOND 1 and 2) with over 800 patients enrolled, and readouts are expected around Q2 2026. If those hit, they're looking at an NDA submission in Q4. For context, the US DME market alone is around $3 billion, but they're pointing out that most of the 1.8 million diagnosed patients aren't even getting properly managed - so there's real unmet need.

What's probably more exciting though is their neuroprotection program, Privosegtor. This one already got Breakthrough Therapy designation based on Phase 2 results in optic neuritis. They showed some pretty substantial vision improvements compared to placebo. The company just kicked off their PIONEER program after meeting with FDA - that's a multi-trial initiative targeting optic neuritis and anterior ischemic optic neuropathy. They estimate this space could be worth over $7 billion in the US alone.

Then there's their precision medicine play with Licaminlimab for dry eye disease. They're running PREDICT-1 with a genotype-based approach - basically targeting patients with specific genetic markers. In Phase 2, they saw 5 to 7-fold greater effects in patients carrying certain genotypes. Results expected Q4 2026.

The net loss actually narrowed in Q4 to 23.51 million Swiss Francs, though full-year losses expanded to about $119.1 million. But honestly, for a biotech with this many clinical readouts coming in the next 18 months, the cash position and pipeline depth is what matters. They're positioned in some pretty massive market opportunities - over $30 billion across their programs if you add it all up.